China’s Drug Clinical Trials Top 5,000, Hitting Record High
China’s drug clinical trial registrations surpassed 5,000 for the first time in 2025, reaching 5,215 — a new historical high that more than doubles the figure recorded in 2020, according to a report released by the National Medical Products Administration (NMPA) on June 22. The milestone underscores China’s rapidly expanding role in global pharmaceutical research and development, with implications for drug innovation, regulatory efficiency, and international competitiveness.
A Decade of Transformation
China has undergone a dramatic transformation in pharmaceutical R&D over the past decade. Once known primarily as a manufacturing hub for generic drugs, the country has invested heavily in building an indigenous innovation ecosystem. The latest data from the NMPA’s Center for Drug Evaluation (CDE) shows that the upward trajectory has been sustained: clinical trial registrations rose from 4,300 in 2023 to 4,900 in 2024, and then to 5,215 in 2025 — a 6.4% year-on-year increase.
According to Yicai Global, 2,997 of the registered trials (57.5% of the total) were for new drugs, marking an 18% year-on-year increase. The remaining 2,218 trials were bioequivalence studies testing the performance of generic drugs.
Innovation at the Forefront
A striking feature of the 2025 data is the dominance of Class 1 innovative drugs — first-in-class global innovative pharmaceuticals. Of the new drug trials, 2,171 (72%) were for Class 1 innovative drugs, with nearly 38% of those focused on anti-tumor treatments. Almost 43% of these innovative drug tests were Phase I trials, reflecting early-stage innovation capacity.
“The high volume of Phase 1 clinical trials reflects China’s capacity for original pharmaceutical innovation,” said Li Ning, chief physician at the Clinical Trial Center of the National Cancer Center of China, as reported by Yicai Global. Li noted that the number of Phase I clinical trials in China surpassed that of the United States in 2025, ranking first globally. He added that the trials “cover novel therapeutic targets and innovative drug development modalities, including cell therapy and gene therapy.”
Accelerating Patient Access
Chinese drug regulators have prioritized speeding up the clinical trial process to bring high-quality medicines to patients faster. The China Daily reported that the average time from regulatory approval to first subject enrollment was shortened by four months in 2025 compared to the previous year. A record-high 74.2% of projects secured informed consent from their first enrolled subjects within six months of approval, up from 66% in 2024.
In total, 248 new drugs were approved for market entry in 2025, spanning 18 therapeutic areas including oncology, endocrinology, and mental disorders. The CDE processed 19,375 drug registration applications — also a record high and a 6.11% increase year-on-year.
Global Integration and Geopolitical Dimensions
China’s clinical trial ecosystem is increasingly integrated into global drug development networks. Nearly 14% of new clinical trial registrations in 2025 were for multi-regional studies, covering sites across more than 70 countries and regions. The United States hosted the largest number of overseas trial sites for Chinese-sponsored studies (22%), followed by Japan, Germany, Spain, and Italy.
However, this rapid growth has not gone unnoticed internationally. The South China Morning Post reported that China’s biotech surge has sparked US security concerns, with the Biden administration and subsequent administrations scrutinizing Chinese biotech firms. Some have been placed on trade restriction lists amid legislative efforts such as the US Biosecure Act.
Trials remain concentrated in China’s wealthier coastal regions — Beijing, Shanghai, Guangdong Province, and Jiangsu Province — while Chinese companies and institutions initiated or funded 93% of all registered trials, with 92% conducted within China.
What This Means for Global Drug Development
The milestone signals a fundamental shift in the global pharmaceutical landscape. China’s transition from a “fast follower” to an “innovator” in drug development is evidenced by the high proportion of Class 1 innovative drugs and the global leadership in Phase I trials. The country’s large patient population, improving regulatory environment, and growing R&D investment make it an increasingly attractive destination for clinical research.
At the same time, the growth rate has moderated — from 13.9% between 2023 and 2024 to 6.4% between 2024 and 2025 — suggesting possible maturation or capacity constraints. Questions also remain about data quality, regulatory enforcement, and the long-term impact of geopolitical tensions on international collaboration.
Looking Ahead
As China continues to invest in biotech as a strategic industry under national initiatives such as Health China 2030, the trajectory of clinical trial growth is expected to continue. Key areas to watch include the success rates of Phase I-to-Phase II transitions, the impact of US-China tensions on research partnerships, and whether China can sustain its momentum as an emerging powerhouse in global pharmaceutical innovation.